...
首页> 外文期刊>Annals of neurology >PDXK PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation
【24h】

PDXK PDXK mutations cause polyneuropathy responsive to pyridoxal 5′‐phosphate supplementation

机译:PDXK PDXK突变引起吡哆醛5'-磷酸盐补充剂的多发性病变

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To identify disease‐causing variants in autosomal recessive axonal polyneuropathy with optic atrophy and provide targeted replacement therapy. Methods We performed genome‐wide sequencing, homozygosity mapping, and segregation analysis for novel disease‐causing gene discovery. We used circular dichroism to show secondary structure changes and isothermal titration calorimetry to investigate the impact of variants on adenosine triphosphate (ATP) binding. Pathogenicity was further supported by enzymatic assays and mass spectroscopy on recombinant protein, patient‐derived fibroblasts, plasma, and erythrocytes. Response to supplementation was measured with clinical validated rating scales, electrophysiology, and biochemical quantification. Results We identified biallelic mutations in PDXK in 5 individuals from 2 unrelated families with primary axonal polyneuropathy and optic atrophy. The natural history of this disorder suggests that untreated, affected individuals become wheelchair‐bound and blind. We identified conformational rearrangement in the mutant enzyme around the ATP‐binding pocket. Low PDXK ATP binding resulted in decreased erythrocyte PDXK activity and low pyridoxal 5′‐phosphate (PLP) concentrations. We rescued the clinical and biochemical profile with PLP supplementation in 1 family, improvement in power, pain, and fatigue contributing to patients regaining their ability to walk independently during the first year of PLP normalization. Interpretation We show that mutations in PDXK cause autosomal recessive axonal peripheral polyneuropathy leading to disease via reduced PDXK enzymatic activity and low PLP. We show that the biochemical profile can be rescued with PLP supplementation associated with clinical improvement. As B 6 is a cofactor in diverse essential biological pathways, our findings may have direct implications for neuropathies of unknown etiology characterized by reduced PLP levels. ANN NEUROL 2019;86:225–240
机译:目的鉴定具有视神经萎缩的常染色体隐性轴突性多变病变中的疾病变异,并提供靶向替代疗法。方法对新型疾病引发基因发现进行了基因组宽测序,纯合理测绘和分离分析。我们使用圆形二中间作用来显示二级结构变化和等温滴定热量,以研究变体对三磷酸(ATP)结合的影响。通过在重组蛋白,患者衍生的成纤维细胞,血浆和红细胞上进一步支持致病性和质谱。用临床验证评级尺度,电生理学和生物化学定量测量补充补充的反应。结果我们在具有2个无关家族的PDXK中鉴定了PDXK中的双胞胎突变,其具有初级轴突性多发性病变和视神经萎缩。这种疾病的自然历史表明,受影响的受影响的人成为轮椅束缚和盲目。我们在ATP结合口袋周围的突变酶中确定了构象重新排列。低PDXK ATP结合导致红细胞PDXK活性和低吡哆醛5'-磷酸(PLP)浓度降低。我们救出了1个家庭的PLP补充剂的临床和生化型材,提高了力量,疼痛和疲劳,促使在PLP标准化的第一年恢复独立行走的能力。解释我们表明PDXK中的突变导致通过降低的PDXK酶活性和低PLP导致常染色体隐性轴心外周多发性多变病变导致疾病。我们表明,可以使用与临床改进相关的PLP补充来救出生化型材。由于B 6是各种必要的生物途径的辅助因子,我们的研究结果可能对特征的未知病因的神经病具有直接影响,其特征在于PLP水平降低。 Ann Neurol 2019; 86:225-240

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号